Yonsei Fraunhofer IZFP Medical Device Lab YFMED

Filters

2
2
2
2
Reset filters

Settings
Now showing 1 - 2 of 2
No Thumbnail Available
Publication

Coptis japonica Makino extract suppresses Angiogenesis through regulation of cell cycle-related proteins

2016 , Kim, S.H. , Kim, E.-C. , Kim, W.-J. , Lee, M.-H. , Kim, S.-Y. , Kim, T.-J.

Angiogenesis, neovascularization from pre-existing vessels, is a key step in tumor growth and metastasis, and anti-angiogenic agents that can interfere with these essential steps of cancer development are a promising strategy for human cancer treatment. In this study, we characterized the anti-angiogenic effects of Coptis japonica Makino extract (CJME) and its mechanism of action. CJME significantly inhibited the proliferation, migration, and invasion of vascular endothelial growth factor (VEGF)-stimulated HUVECs. Furthermore, CJME suppressed VEGF-induced tube formation in vitro and VEGF-induced microvessel sprouting ex vivo. According to our study, CJME blocked VEGF-induced cell cycle transition in G1. CJME decreased expression of cell cycle-regulated proteins, including Cyclin D, Cyclin E, Cdk2, and Cdk4 in response to VEGF.

View
No Thumbnail Available
Publication

Effect of nodakenin on atopic dermatitis-like skin lesions

2014 , Park, S.-J. , Cha, H.-S. , Lee, Y.-H. , Kim, W.-J. , Kim, D.-H. , Kim, E.-C. , Lee, K.-H. , Kim, T.-J.

Nodakenin, derived from the roots of Angelica gigas Nakai, is an important natural resource and medicinal material with anti-allergic and anti-inflammatory activities. We have previously shown that nodakenin inhibits IgE/Ag-induced degranulation in mast cells. In this study, we investigated the inhibitory effect of nodakenin on 2,4-dinitrochloro-benzene (DNCB)-induced atopic dermatitis (AD)-like skin lesions in ICR mice. Scratching behavior, skin severity score, blood IgE level, and skin thickness were improved in DNCB-induced AD-like ICR mice. Our results showed that nodakenin suppressed the increase of AD-like skin lesions in ICR mice. These results suggest that nodakenin may be a potential therapeutic resource for AD as well as an adjunctive agent to control itching associated with AD.

View